Brooklyn ImmunoTherapeutics (NYSE:BTX) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report report published on Saturday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

NYSE:BTX opened at $2.15 on Friday. The firm has a market capitalization of $126.48 million, a price-to-earnings ratio of -0.95 and a beta of 4.61. The company’s 50-day moving average is $2.14 and its two-hundred day moving average is $1.81. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.